VM — Voyageur Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- CA$28.90m
- CA$28.77m
- 19
- 11
- 89
- 33
Annual income statement for Voyageur Pharmaceuticals, fiscal year end - November 30th, CAD millions except per share, conversion factor applied.
2020 November 30th | 2021 November 30th | 2022 November 30th | 2023 November 30th | 2024 November 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 1.15 | 2.05 | 1.75 | 1.4 | 1.71 |
| Operating Profit | -1.15 | -2.05 | -1.75 | -1.4 | -1.71 |
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -1.14 | -2.05 | -1.75 | -1.4 | -1.71 |
| Net Income After Taxes | -1.14 | -2.05 | -1.75 | -1.4 | -1.71 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -1.14 | -2.05 | -1.75 | -1.4 | -1.71 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1.14 | -2.05 | -1.75 | -1.4 | -1.71 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.014 | -0.022 | -0.016 | -0.01 | -0.012 |